Visual improvement after corneal collagen cross-linking in keratoconus
Open Access
- 15 December 2022
- journal article
- Published by IP Innovative Publication Pvt Ltd in Indian Journal of Clinical and Experimental Ophthalmology
- Vol. 8 (4), 468-473
- https://doi.org/10.18231/j.ijceo.2022.095
Abstract
This study was carried out to evaluate the effect of corneal collagen cross-linking on visual acuity, astigmatism and topographic readings (K1, K2, Kapex). : A nonrandomized noncontrolled clinical study was conducted in two tertiary eye centres in Bangladesh from July 2017 to June 2019. All attending patients diagnosed with Keratoconus were included in this study according to selection criteria. Patients with a corneal thickness of fewer than 400 microns, previous viral infection, cornea scarring, corneal opacification, severe ocular surface disease, history of immune disorders, pregnancy, and breastfeeding were excluded from the study. All selected patients underwent collagen cross-linking with Riboflavin and Ultraviolet A, followed up five days, one and six months following the procedure. Visual acuity, topographic readings (K1, K2, Kapex) and cylindrical values were assessed on every visit. The mean value of visual acuity was compared statistically with the baseline value.: A total of 30 eyes of 30 patients were studied in this study. The male-to-female ratio was 2:1. The Mean age (± SD) of the study subjects was 22.7±7.10. Before CXL, the Mean uncorrected visual acuity (UCVA) ±SD was 0.86±.35. In post-CXL follow-up time, the mean UCVA±SD was 0.46±.23 after six months of CXL. Before CXL, the Mean BCVA±SD was 0.35±.22. In post CXL era, the Mean ± SD BCVA was 0.14±.13 after six months of CXL. The Mean K1±SD was 45.66±3.43 before CXL, and the result changed after CXL. The Mean K1±SD was 43.29±3.29 after six months of CXL. The Mean K2±SD was 50.22±5.93 before CXL, and the result differed after six months of CXL. The Mean Kapex ±SD was 54.50±7.38 before CXL, and that was 51.32±6.93 after six months of CXL. Keratoconus is a bilateral non-inflammatory disorder progressively leading to vision-threatening ocular morbidity. Collagen cross-linking improves visual and topographic findings– K1, K2, and Kapex and reduces astigmatism. Early diagnosis of Keratoconus and prompt treatment will help achieve better vision.Keywords
This publication has 21 references indexed in Scilit:
- Corneal Collagen Cross-Linking for Keratoconus in Pediatric Patients—Long-Term ResultsCornea, 2017
- Standard versus trans-epithelial collagen cross-linking in keratoconus patients suitable for standard collagen cross-linkingClinical Ophthalmology, 2015
- Safety and efficacy of epithelium removal and transepithelial corneal collagen crosslinking for keratoconusEye, 2014
- Efficacy of Corneal Collagen Crosslinking with Riboflavin and Ultraviolet A in Progressive KeratoconusDelhi Journal of Ophthalmology, 2013
- Transepithelial corneal collagen cross‐linking by iontophoresis of riboflavinActa Ophthalmologica, 2013
- Corneal Crosslinking with Riboflavin and Ultraviolet A. I. PrinciplesThe Ocular Surface, 2013
- Progression of Keratoconus and Efficacy of Corneal Collagen Cross-linking in Children and AdolescentsJournal of Refractive Surgery, 2012
- Transepithelial corneal collagen crosslinking: Bilateral studyJournal of Cataract & Refractive Surgery, 2012
- Progression of Keratoconus by Longitudinal Assessment with Corneal TopographyInvestigative Ophthalmology & Visual Science, 2012
- Riboflavin/ultraviolet-a–induced collagen crosslinking for the treatment of keratoconusAmerican Journal of Ophthalmology, 2003